Viridian’s $150M offering; Surrozen scraps IBD drug candidate; Assembly ends deal with Indiana University

Plus, news about Vor Bio, Vaxxin­i­ty, Im­mat­ics and Cer­tis On­col­o­gy:

Virid­i­an Ther­a­peu­tics’ $150M pub­lic of­fer­ing: The Waltham, MA-based biotech is sell­ing about 7.1 mil­lion shares of its com­mon stock at $21.00 per share, ex­pect­ing to bring in $150 mil­lion to help ad­vance its clin­i­cal pro­grams. Its stock $VRDN was down about 6% in trad­ing on Thurs­day morn­ing. Back in Oc­to­ber, the com­pa­ny an­nounced a $185 mil­lion pri­vate place­ment when it ap­point­ed for­mer Ma­gen­ta Ther­a­peu­tics ex­ec Stephen Ma­honey as its new CEO. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.